Detail akcie Vericel online

Business Summary: Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vericel Corp revenues increased 13% to $183.3M. Net loss decreased 29% to $6.7M. Revenues reflect MACI segment increase of 83% to $155.4M, NexoBrid segment increase from $1.5M to $4M, Epicel segment increase of 5% to $24M, United States segment increase of 66% to $183.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.19 to -$0.14.